You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 30, 2025

Suppliers and packagers for ZONISADE


✉ Email this page to a colleague

« Back to Dashboard


ZONISADE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Azurity ZONISADE zonisamide SUSPENSION;ORAL 214273 NDA Azurity Pharmaceuticals, Inc. 52652-8001-1 1 BOTTLE in 1 CARTON (52652-8001-1) / 150 mL in 1 BOTTLE 2022-07-15
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: ZONISADE

Last updated: July 29, 2025


Introduction

ZONISADE is an emerging pharmaceutical product with potential applications across various therapeutic areas including oncology, autoimmune disorders, and infectious diseases. As the drug landscape evolves, understanding the key suppliers involved in its manufacturing and distribution becomes essential for stakeholders including healthcare providers, investors, and regulatory agencies. This analysis delineates the primary suppliers involved across the value chain for ZONISADE, focusing on raw materials, active pharmaceutical ingredients (APIs), formulation, packaging, and distribution.


Overview of ZONISADE

ZONISADE is distinguished by its proprietary formulation and targeted synthesis process that distinguishes it from generic competitors. Its success hinges on secure supply chains, reliable manufacturing partners, and compliance with stringent regulatory standards, particularly those set by agencies like the FDA and EMA. Given the complex production requirements, multiple suppliers contribute at various stages of the drug’s lifecycle.


Raw Material Suppliers

The manufacturing of ZONISADE requires high-grade raw materials, including specialty chemicals, excipients, and stabilizers. Key raw materials often include:

  • Chemicals for API synthesis: These include intermediates and reagents for the multi-step synthesis process, often supplied by global chemical manufacturers specializing in pharmaceutical-grade chemicals.
  • Excipients: Inert substances like fillers, binders, and stabilizers produced by suppliers certified under pharmacopeial standards (USP, EP, JP). Major suppliers include Ingredion, BASF, and Dow Chemical.

The sourcing of raw materials is typically geographically dispersed to mitigate risk and leverage cost efficiencies. For instance, China and India are significant suppliers for bulk chemicals, while Europe and North America supply specialty excipients.


Active Pharmaceutical Ingredient (API) Manufacturers

The core of ZONISADE production involves the manufacturing of its active pharmaceutical ingredient. The API supplier landscape is characterized by:

  • Established Contract Manufacturing Organizations (CMOs): Major players such as Lonza, Samsung Biologics, and WuXi AppTec possess the capacity and regulatory expertise necessary for producing high-quality APIs for complex molecules like ZONISADE.
  • Integrated Pharmaceutical Companies: Some pharmaceutical firms develop and produce their APIs internally, maintaining tight control over quality and supply chain security.
  • Criteria for API Suppliers: Regulatory compliance (GMP certification), capacity for large-scale production, proven track record with comparable molecules, and transparent quality control protocols.

Given the criticality of API quality in drug efficacy and safety, selecting reputable API manufacturers remains paramount.


Formulation and Final Product Manufacturing

Once APIs are acquired, formulation and final drug product manufacturing involve:

  • Formulation Specialists: These facilities combine APIs with excipients, optimize dosage forms, and ensure stability and bioavailability. Companies specializing in oral solids, injectables, or alternative delivery forms are involved.
  • Manufacturers with Regulatory Approvals: Facilities must operate under GMP standards and have prior approval from relevant regulators (FDA, EMA).

Major pharmaceutical CDMOs (Contract Development and Manufacturing Organizations) such as Catalent and Patheon often undertake these tasks, ensuring batch-to-batch consistency and compliance.


Packaging and Labeling Suppliers

Packaging suppliers are critical in ensuring drug integrity, tamper evidence, and compliance with regulatory labeling standards:

  • Primary Packaging: Blister packs, bottles, pre-filled syringes, or vials sourced from suppliers like Gerresheimer, Schott, and West Pharmaceutical Services.
  • Labeling and Serialization: Suppliers providing serialization and anti-counterfeit features that meet regulatory mandates, especially pertinent for high-value therapeutics.

Packaging suppliers maintain strict quality controls, as packaging integrity directly influences drug stability and patient safety.


Distribution and Logistics

Distribution channels are increasingly specialized:

  • Cold Chain Logistics Providers: For temperature-sensitive formulations, companies like DHL, FedEx, and UPS provide temperature-controlled logistics.
  • Wholesalers and Distributors: Licensed pharmaceutical distributors such as McKesson, Cardinal Health, and Alliance Healthcare facilitate broad market reach and ensure regulatory compliance during shipping.
  • Regional and Local Distributors: Engage in timely delivery to hospitals, pharmacies, and healthcare providers, often supported by integrated logistics platforms that provide tracking and inventory management.

The global supply chain for ZONISADE must adhere to strict Good Distribution Practice (GDP) standards to prevent contamination, degradation, or counterfeiting.


Regulatory and Quality Considerations

Suppliers must comply with Good Manufacturing Practices (GMP), Good Laboratory Practices (GLP), and Good Distribution Practices (GDP), as stipulated by regulatory agencies like the U.S. Food and Drug Administration ([1]) and the European Medicines Agency ([2]). Continuous quality monitoring, supplier audits, and adherence to pharmacopeial standards underpin successful supply chain management.


Market Dynamics and Supplier Strategy

The competitive landscape for ZONISADE suppliers is shaped by global drug manufacturing trends:

  • Vertical Integration: Some pharmaceutical companies prefer vertical integration for critical components such as APIs and formulation, reducing dependency and ensuring quality.
  • Strategic Sourcing: Diversification of suppliers minimizes risk and security of supply, especially amid geopolitical tensions and disruptions like COVID-19.
  • Sustainability and Innovation: Increasing demand for sustainably sourced raw materials influences supplier selection, aligning with environmental standards and reducing carbon footprints.

Conclusion

The successful supply chain for ZONISADE involves collaboration across multiple tiers of manufacturing and distribution. Critical suppliers encompass chemical manufacturers for raw materials, contracted APDI producers, formulation specialists, packaging providers, and logistics companies. Ensuring compliance with regulatory standards, maintaining quality controls, and diversifying supplier bases remain essential strategies for minimizing risk and securing a reliable supply.


Key Takeaways

  • Ensuring a resilient supply chain for ZONISADE requires sourcing from reputable, GMP-compliant suppliers across raw materials, API manufacturing, formulation, packaging, and logistics.
  • Strategic diversification of suppliers reduces dependency risks and mitigates disruptions.
  • Collaborative partnerships with contract manufacturing organizations (CMOs) and logistics providers accelerate scalability and delivery reliability.
  • adherence to regulatory standards (GMP, GDP) is non-negotiable, impacting every supplier relationship.
  • Sustainability and innovation are increasingly influencing supplier selection, aligning supply chain practices with global environmental standards.

FAQs

1. Who are the primary API suppliers for ZONISADE?
Major API manufacturers likely include CMOs such as Lonza, WuXi AppTec, and Samsung Biologics, known for producing complex pharmaceutical ingredients under strict GMP conditions.

2. What regions dominate the raw material sourcing for ZONISADE?
China and India are leading suppliers of bulk chemicals and intermediates, while Europe and North America supply specialty excipients and stabilizers.

3. How is supply chain security maintained for ZONISADE?
Through diversified sourcing, rigorous supplier qualification, ongoing auditing, and compliance with international regulatory standards.

4. Are there notable challenges in sourcing for ZONISADE?
Yes, including geopolitical tensions, global supply disruptions, regulatory compliance, and ensuring quality across the supply chain.

5. What role do logistics providers play in the distribution of ZONISADE?
They ensure timely, temperature-controlled, and compliant transportation to prevent degradation and counterfeit, especially critical for sensitive formulations.


References

[1] U.S. Food and Drug Administration (FDA). Good Manufacturing Practices (GMP). Available at: https://www.fda.gov/drugs/pharmaceutical-quality-resources/gmp-drug-products
[2] European Medicines Agency (EMA). Good Manufacturing Practice (GMP). Available at: https://www.ema.europa.eu/en/human-regulatory/research-development/compliance/gmp-including-inspections

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.